Use of TNF (tumour necrosis factor)-Blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis.

Trial Profile

Use of TNF (tumour necrosis factor)-Blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Prednisone; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 01 Aug 2013 Results published in the Annals of the Rheumatic Diseases.
    • 30 Jun 2012 Results published in Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top